We injected WT (W) and Grn−/− (G) mice with control or AD patient–derived tau at 3 months of age, whereas aged WT (AW) and Tmem106b−/− (T) mice were 19 months old at the time of injection and 25 months at the end of the experiment (Fig. 7A). This evidence concerns the gene MAPT and Alzheimer disease.